Cargando…

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment

Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of bromodomain and extraterminal (BET) proteins, which are epigenetic readers that modulate gene expression. In the phase 3 BETonMACE trial, apabetalone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D., Fu, Li, Tsujikawa, Laura M., Sarsons, Christopher D., Carestia, Agostina, Lebioda, Kenneth, Johansson, Jan O., Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295623/ https://www.ncbi.nlm.nih.gov/pubmed/37371758 http://dx.doi.org/10.3390/biomedicines11061663

Ejemplares similares

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

Benefit of Apabetalone on Plasma Proteins in Renal Disease
por: Wasiak, Sylwia, et al.
Publicado: (2017)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
por: Fu, Li, et al.
Publicado: (2023)

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019)

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
por: Fu, Li, et al.
Publicado: (2022)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021)

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022)

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
por: Haarhaus, Mathias, et al.
Publicado: (2020)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

The Influence of a Nanopatterned Scaffold that Mimics Abnormal Renal Mesangial Matrix on Mesangial Cell Behavior
por: Chang, Chia-Jung, et al.
Publicado: (2019)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus
por: Wright, Rachael D., et al.
Publicado: (2019)

Effect of Cysteine on Methylglyoxal-Induced Renal Damage in Mesangial Cells
por: Lee, Jae Hyuk, et al.
Publicado: (2020)

Inflammatory and Fibrotic Mediators in Renal Diseases
por: Rayego-Mateos, Sandra, et al.
Publicado: (2019)

Understanding the Renal Fibrotic Process in Leptospirosis
por: Prado, Luan Gavião, et al.
Publicado: (2021)

Calcification of Renal Tumours
por: Aldrich, Herschel C.
Publicado: (1939)

Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease
por: Chua, Janice T., et al.
Publicado: (2019)

Erythropoietin protects lipopolysaccharide-induced renal mesangial cells from autophagy
por: BI, LINGYUN, et al.
Publicado: (2015)

Sauchinone Protects Renal Mesangial Cell Dysfunction against Angiotensin II by Improving Renal Fibrosis and Inflammation
por: Yoon, Jung Joo, et al.
Publicado: (2020)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients
por: Kalantar-Zadeh, Kamyar
Publicado: (2012)

Patient education for phosphorus management in chronic kidney disease
por: Kalantar-Zadeh, Kamyar
Publicado: (2013)

Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy
por: Brunskill, Eric W, et al.
Publicado: (2012)

Renal stromal miRNAs are required for normal nephrogenesis and glomerular mesangial survival
por: Phua, Yu Leng, et al.
Publicado: (2015)

Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and non-resistant hypertension
por: Sim, John J., et al.
Publicado: (2015)

Association of Serum Triglycerides and Renal Outcomes among 1.6 Million US Veterans
por: Soohoo, Melissa, et al.
Publicado: (2022)

THE BIPHASIC NATURE OF RENAL CALCIFICATION
por: Dahl, Lewis K., et al.
Publicado: (1952)

Renal tuberculosis with lobar calcification
por: Balani, A., et al.
Publicado: (2016)

Anti-Renal Fibrotic Effect of Exercise Training in Hypertension
por: Huang, Chiu-Ching, et al.
Publicado: (2018)

New insights into fibrotic signaling in renal cell carcinoma
por: Chen, Jiao-Yi, et al.
Publicado: (2023)

Sirolimus Enhances Cyclosporine A-Induced Cytotoxicity in Human Renal Glomerular Mesangial Cells
por: O'Connell, Séin, et al.
Publicado: (2012)

In vitro silencing of the insulin receptor attenuates cellular accumulation of fibronectin in renal mesangial cells
por: Yano, Naohiro, et al.
Publicado: (2012)

Small Peptides Able to Suppress Prostaglandin E(2) Generation in Renal Mesangial Cells
por: Vasilakaki, Sofia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3mqaip2s66dfmdlg1ave19r9nu